Kết quả điều trị u nguyên bào thần kinh đệm tại Bệnh Viện Trung ương Quân Đội 108

To evaluate the results of glioblastoma treatment at 108 Military Central Hospital. Subjects and methods: Retrospective descriptive study on 79 glioblastoma patients from 1/2018 to 12/2023, who underwent surgery, radiotherapy, and adjuvant chemotherapy. Results: In the study, 28/79 (35.4%) patients underwent gross total resection (GTR), 19% subtotal resection (STR), 34.2% partial resection (PR), and 11.4% biopsy. MGMT gene methylation status was detected in 12/33 (36.4%), 16/43 (37.2%) patients with IDH1 gene mutation. The median overall survival (OS) and progression-free survival (PFS) were 20 months and 15 months, respectively. At 1 year and 2 years, the OS rates were 84.5% and 36.2%, respectively, and the PFS rates were 60% and 19.5%. The median OS, PFS of the group of patients with MGMT methylation status was significantly higher than that of the group without MGMT methylation (OS 36 months and 16 months (p= 0.003), PFS 22 months and 12 months (p= 0.018)). The median OS of GTR/STR group was 24 months, and the group with PR/biopsy was 17 months (p= 0.012). PFS between these 2 groups was 17 months and 11 months, respectively (p= 0.023). The median OS of the group with RPA 3+4 and the group with RPA 5+6 was 21 months and 15 months (p=0.016). Grade 3+4 adverse events were only seen in 2 patients with increased GOT/GPT (2.5%), and 2 patients with grade 3+4 leukopenia and thrombocytopenia, the rest were mostly grade 1+2. Conclusion: The study showed that the surgical regimen combined with chemotherapy and radiotherapy is still the standard regimen, safe and well tolerated for GBM patients. The study also showed that MGMT methylation status, extent of tumor resection, and RPA had a significant impact on OS and PFS survival time.